Conditions:   Bladder Cancer;   Cervical Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Long-term Effects Secondary to Cancer Therapy in Adults;   Ovarian Cancer;   Prostate Cancer;   Radiation Toxicity;   Sarcoma;   Testicular Germ Cell Tumor;   Vaginal Cancer
Interventions:   Other: questionnaire administration;   Procedure: gastrointestinal complications management/prevention;   Procedure: quality-of-life assessment
Sponsor:   Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: systemic chemotherapy;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
Sponsor:   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Leukemia;   Mucositis;   Oral Complications
Interventions:   Biological: epratuzumab;   Biological: palifermin;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: imatinib mesylate;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: vincristine sulfate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Radiation: total-body irradiation
Sponsor:   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsor:   University College London Hospitals
Recruiting - verified March 2010

Condition:   Bacterial Infections
Intervention:   Biological: Gut infection challenge with M bovis
Sponsors:   St George's, University of London;   University of British Columbia;   Wellcome Trust;   Fundação Ataulpho de Paiva, Rio de Janeiro, Brasil;   Foundation for the National Institutes of Health;   Bill and Melinda Gates Foundation
Completed - verified February 2010

Condition:   Cancer
Interventions:   Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
Sponsor:   University Hospital Birmingham
Recruiting - verified September 2009

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Cancer Research UK
Recruiting - verified August 2009

Condition:   Sexually Transmitted Diseases, Viral
Interventions:   Biological: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads;   Biological: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
Sponsors:   St George's, University of London;   European Union
Active, not recruiting - verified February 2010

Condition:   HIV
Interventions:   Drug: atazanavir/raltegravir;   Drug: atazanavir/raltegravir;   Drug: atazanavir/tenofovir/emtricitabine
Sponsor:   Community Research Initiative of New England
Recruiting - verified February 2010

Conditions:   Atrial Fibrillation;   Arrhythmia;   Stroke Prevention;   Mortality
Interventions:   Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Sponsors:   Mayo Clinic;   National Heart, Lung, and Blood Institute (NHLBI);   Duke University;   St. Jude Medical;   Biosense Webster, Inc.
Recruiting - verified February 2010

Condition:   Bladder Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsor:   Institute of Cancer Research, United Kingdom
Active, not recruiting - verified March 2009

Conditions:   Bladder Cancer;   Brain and Central Nervous System Tumors;   Esophageal Cancer;   Intraocular Melanoma;   Kidney Cancer;   Lymphoma;   Melanoma (Skin);   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration
Sponsor:   Cancer Research UK
Recruiting - verified September 2008

Conditions:   Chemotherapeutic Agent Toxicity;   Lymphoma;   Mucositis;   Neurotoxicity
Interventions:   Drug: glucarpidase;   Drug: leucovorin calcium;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: radiation therapy
Sponsor:   Cancer Research UK
Recruiting - verified November 2008

Condition:   Type 1 Diabetes Mellitus
Interventions:   Biological: otelixizumab;   Biological: placebo
Sponsors:   Tolerx Inc.;   Juvenile Diabetes Research Foundation
Active, not recruiting - verified March 2009

Conditions:   Glioblastoma;   Gliosarcoma
Intervention:   Drug: Temozolomide
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   University of Pennsylvania;   Wake Forest University;   Tufts Medical Center;   Dartmouth-Hitchcock Medical Center;   Schering-Plough
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Procedure: quality-of-life assessment;   Procedure: questionnaire administration
Sponsor:   University of Birmingham
Recruiting - verified February 2010

Condition:   HIV Infections
Interventions:   Drug: dual boosted protease inhibitor;   Drug: darunavir
Sponsor:   Community Research Initiative of New England
Completed - verified October 2008

Condition:   Cancer
Interventions:   Genetic: polymerase chain reaction;   Other: bronchoalveolar lavage;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Procedure: bronchoscopy;   Procedure: management of therapy complications
Sponsor:   St. Bartholomew's Hospital
Recruiting - verified September 2007

Conditions:   Lymphoma;   Neutropenia;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsor:   Clatterbridge Centre for Oncology
Recruiting - verified May 2007

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Myopia
Interventions:   Device: Progressive Addition Lenses (PALs);   Device: Single Vision Lenses (SVLs)
Sponsors:   Jaeb Center for Health Research;   National Eye Institute (NEI)
Active, not recruiting - verified January 2010

Condition:   Lymphoma
Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: pharmacological study;   Radiation: radiation therapy
Sponsor:   German High-Grade Non-Hodgkin's Lymphoma Study Group
Recruiting - verified July 2009

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: resveratrol
Sponsors:   University of Michigan Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate
Sponsors:   European Organization for Research and Treatment of Cancer;   Lymphoma Trials Office;   Groupe d'Etudes de Lymphomes de L'Adulte;   Grup per l'Estudi dels Limfomes de Catalunya i Balears;   NCIC Clinical Trials Group;   Australasian Leukaemia and Lymphoma Group (ALLG);   Nordic Lymphoma Group
Active, not recruiting - verified June 2009

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy
Sponsor:   Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified March 2007

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisolone;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation
Sponsor:   Dutch Childhood Oncology Group
Active, not recruiting - verified October 2006

Conditions:   Brain and Central Nervous System Tumors;   Breast Cancer;   Extragonadal Germ Cell Tumor;   Infection;   Lung Cancer;   Lymphoma;   Ovarian Cancer;   Small Intestine Cancer;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: levofloxacin
Sponsor:   Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified July 2002

Condition:   Prostate Cancer
Interventions:   Biological: luteinizing hormone-releasing factor;   Radiation: radiation therapy
Sponsor:   Medical Research Council
Active, not recruiting - verified July 2001

Condition:   Head and Neck Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate;   Radiation: low-LET cobalt-60 gamma ray therapy;   Radiation: low-LET photon therapy;   Radiation: radiation therapy
Sponsor:   Cancer Research UK
Active, not recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsor:   Medical Research Council
Active, not recruiting - verified April 1999

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Medical Research Council;   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified September 2005